Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2018

Dec 20, 2023

BUY
$0.83 - $4.16 $322 - $1,614
388 New
388 $1.57 Million
Q2 2017

Dec 21, 2023

SELL
N/A
-9,312 Reduced 96.0%
388 $865,000
Q4 2016

Dec 21, 2023

BUY
N/A
9,700
9,700 $652,000

Others Institutions Holding CVM

About CEL SCI CORP


  • Ticker CVM
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,367,500
  • Market Cap $33.4M
  • Description
  • CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...
More about CVM
Track This Portfolio

Track West Paces Advisors Inc. Portfolio

Follow West Paces Advisors Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of West Paces Advisors Inc., based on Form 13F filings with the SEC.

News

Stay updated on West Paces Advisors Inc. with notifications on news.